TY - JOUR
T1 - Susceptibility of various clinical pathogens to tigecycline in the Tohoku area, Japan
AU - Hayakawa, Sachiko
AU - Fujimura, Shigeru
AU - Watanabe, Yuji
AU - Furukawa, Emiko
AU - Kawamura, Masato
AU - Uno, Koichi
AU - Sato, Toshio
AU - Watanabe, Akira
PY - 2015/11
Y1 - 2015/11
N2 - Tigecycline was released in Japan from September, 2012. Bacterial indications are multidrug-resistant Acinetobacter baumannii, NDM-1-producing Escherichia coli, and other multidrug-resistant gram-negative bacilli. Tigecycline had been already used in the US and Europe, and was swiftly introduced into Japan. Therefore, there are few antibiotic susceptibility data for a variety of clinically isolated pathogens in Japan. In this study, we investigated the minimum inhibitory concentration (MIC) of tigecycline against 270 pathogens isolated from patients in 22 hospitals in the Tohoku area, Japan. The MIC was determined with susceptibility testing using the CLSI broth microdilution method. The susceptibility rate of Escherichia coli, Klebsiella spp., and Acinetobacter spp. was demonstrated at 100%. Additionally, the rates of ESBL-producing Enterobacteriaceae and MRSA were 83.1% and 93.3%, respectively. However, 50% of MRSA which demonstrated an MIC for vancomycin of 2 μg/mL showed tigecycline resistance.
AB - Tigecycline was released in Japan from September, 2012. Bacterial indications are multidrug-resistant Acinetobacter baumannii, NDM-1-producing Escherichia coli, and other multidrug-resistant gram-negative bacilli. Tigecycline had been already used in the US and Europe, and was swiftly introduced into Japan. Therefore, there are few antibiotic susceptibility data for a variety of clinically isolated pathogens in Japan. In this study, we investigated the minimum inhibitory concentration (MIC) of tigecycline against 270 pathogens isolated from patients in 22 hospitals in the Tohoku area, Japan. The MIC was determined with susceptibility testing using the CLSI broth microdilution method. The susceptibility rate of Escherichia coli, Klebsiella spp., and Acinetobacter spp. was demonstrated at 100%. Additionally, the rates of ESBL-producing Enterobacteriaceae and MRSA were 83.1% and 93.3%, respectively. However, 50% of MRSA which demonstrated an MIC for vancomycin of 2 μg/mL showed tigecycline resistance.
KW - Acinetobacter spp
KW - Antimicrobial susceptibility
KW - ESBL
KW - MRSA
KW - Tigecycline
UR - http://www.scopus.com/inward/record.url?scp=84951188186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951188186&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84951188186
VL - 63
SP - 576
EP - 579
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 6
ER -